Not medical advice. This site is general information only. In an emergency call your local emergency number. For advice about your own health, speak to a doctor, pharmacist or other qualified health professional.
Palbociclib
About Palbociclib
A CDK4/6 inhibitor that revolutionized treatment of hormone receptor positive breast cancer. Palbociclib or Ibrance treats metastatic breast cancer by blocking proteins that drive cancer cell division. Combined with hormone therapy, it significantly prolongs progression free survival. Palbociclib was the first CDK4/6 inhibitor approved, opening a new class of targeted breast cancer drugs. The main side effect is low blood counts requiring dose adjustments. The drug has become standard first line treatment for metastatic hormone positive breast cancer.
Related Medications
Imatinib
A breakthrough targeted cancer therapy. Imatinib or Gleevec treats chronic myeloid leukemia by specifically in...
Bortezomib
A proteasome inhibitor that revolutionized multiple myeloma treatment. Bortezomib or Velcade treats multiple m...
Erlotinib
An EGFR tyrosine kinase inhibitor. Erlotinib or Tarceva treats non small cell lung cancer with EGFR mutations ...
Crizotinib
A targeted therapy for a rare genetic subtype of lung cancer. Crizotinib or Xalkori treats non small cell lung...